Final Study Record Detail: Efficacy of EGb761 in Patients Suffering From Friedreich Ataxia

Efficacy of EGb761 in Patients Suffering From Friedreich Ataxia. www.clinicaltrials.gov, A service of the U.S. National Institutes of Health.

Study Design:
Allocation: Randomized; Endpoint Classification: Efficacy Study; Intervention Model: Parallel Assignment; Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor); Primary Purpose: Supportive Care

Due to small sample size and considering there are no specific studies in this population with EGb761; calculation with the use of a statistical hypothesis was not possible. Primary efficacy analyses performed on the mITT population and analysis of safety performed on the safety population.